ArticleFrontiers in nutrition2025
Adherence to the Mediterranean diet to prevent or delay hepatic steatosis: a longitudinal analysis within the PREDIMED study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Trial
- Enhancing MAFLD Care: Efficacy of a Multidisciplinary Community Intervention on Self-Management and Hepatic Outcomes.Inquiry : a journal of medical care organization, provision and financingTrial
- The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients · 2026Review
- Rethinking the hepatoprotective potential of vegetarian diets in dysfunction-associated steatotic liver disease/metabolic-associated fatty liver disease: a critical narrative review.Frontiers in nutrition · 2026Review
- Eating behaviors and liver health in metabolic dysfunction-associated fatty liver disease: the serial mediating roles of Mediterranean diet adherence and adiposity.Frontiers in nutrition · 2026Article
- A transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease.Frontiers in pharmacology · 2026Article
- Early-Life Nutritional Determinants of Pediatric MASLD.Nutrients · 2025Review
- The Role of the Mediterranean Diet and Alcohol Consumption in Chronic Liver Disease Prevention: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Optimal Vegetable Intake for Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) Prevention: Insights from a South Italian Cohort.Nutrients · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Little is known about the potential preventive effect of adherence to the Mediterranean diet (MedDiet) on the development of metabolic dysfunction-associated steatotic liver disease (MASLD). Aim: This study aims to determine the impact of adherence to the MedDiet on the progression of MASLD, measured using the hepatic steatosis index (HSI) at baseline and annually over a 5-year follow-up period within the framework of the Method: Participants from the PREDIMED trial with sufficient available data ( Results: The participants (57% female, 43% male) had a mean age of 67.2 (SD 6.2) years. Among the cardiovascular risk factors considered, the mean BMI was 29.81 (SD 3.62); 47% of participants had type 2 diabetes, 70% had hypercholesterolaemia, and 84% had hypertension. Over the 5-year follow-up, average adherence to the MedDiet and physical activity generally increased, while alcohol consumption, calorie intake, tobacco use, hypercholesterolaemia, and hypertension decreased. The fully adjusted multivariate model reflected a statistically significant decrease in the HSI per unit increase in adherence to the MedDiet (β = -0.075; 95% CI: -0.128, -0.021). Conclusion: In individuals at high cardiovascular risk, adherence to the MedDiet is significantly associated with improvements in HSI. These longitudinal findings highlight the important role of the MedDiet in delaying or slowing the natural progression of MASLD, contributing to both its prevention and clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.